Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity.  by Litman, Thomas et al.
 .Biochimica et Biophysica Acta 1361 1997 169–176
Competitive, non-competitive and cooperative interactions between
substrates of P-glycoprotein as measured by its ATPase activity.
Thomas Litman a,b,), Thomas Zeuthen b, Torben Skovsgaard a, Wilfred D. Stein c
a Department of Oncology, Herle˝ Hospital, Uni˝ersity of Copenhagen, Copenhagen, Denmark
b Department of Medical Physiology, The Panum Institute, Uni˝ersity of Copenhagen, Copenhagen, Denmark
c Department of Biochemistry, Silberman Institute of Life Sciences, Hebrew Uni˝ersity, Jerusalem, 91904, Israel
Received 3 January 1997; revised 19 March 1997; accepted 20 March 1997
Abstract
We have studied the interaction between verapamil and other modulators of the P-glycoprotein ATPase from membranes
 .of CR1R12 Chinese hamster ovary cells. Four major categories of interaction were identified. i Non-competitive inhibition
 .of verapamil’s stimulation of enzyme activity was found with vanadate. ii Competitive inhibition of the ATPase was found
 .for the pair verapamil and cyclosporin A. iii Allosteric inhibition with an increase in the Hill number for verapamil was
 .found in the cases of daunorubicin, epirubicin, gramicidin S and D, vinblastine, amiodarone, and colchicine. iv
Cooperative stimulation of verapamil-induced ATPase activity was found with progesterone, diltiazem, amitriptyline, and
propranolol. At high levels, progesterone and verapamil mutually enhanced each other’s inhibitory action on the ATPase.
Our data show that the substrate binding behavior of P-glycoprotein is complex with more than one binding site being
present. This information could form the basis for the development of improved modulators of P-glycoprotein.
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1. Introduction
A major effort is being made to find ways to block
the action of P-glycoprotein which is believed to be
the main mechanism behind multidrug resistance in
w xcancers refractory to chemotherapy 1–4 . Many
modulators of P-glycoprotein have been identified
and some have entered clinical trials, including D-
w x w x w xverapamil 5 , cyclosporin A 6 , and amiodarone 7 .
One strategy for improving clinical responses has
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been to search for more effective modulators, e.g.
w xSandoz PSC-833 8 and Glaxo’s dihydropyridine
w xanalogue teludipine 9 . Another strategy has been to
investigate the use of pairs of reversers in the hope of
finding synergistic effects between them. This latter
wapproach has been pursued at the cellular level 10–
x w x12 , and also at the clinical level 2 . In order to
provide a molecular basis for the further advances in
the study of synergy between reversers, it is neces-
sary to explore reverser-reverser interactions on the
P-glycoprotein itself.
In the preceding paper in this series Litman et al.,
Structure-activity relationships of P-glycoprotein in-
teracting drugs: kinetic characterization of their ef-
.fects on ATPase activity, BBA, this issue we investi-
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gated the effect of a variety of drugs on the ATPase
activity of P-glycoprotein from highly multidrug re-
sistant Chinese hamster ovary cells. We characterized
the kinetic behavior of 34 substances and found that
the affinity of these drugs for P-glycoprotein was
positively correlated with the molecular surface area
of the drugs. In the present paper we deepen the
analysis by studying some of these drugs in pairs so
as to test for interactions between them. Ayesh et al.
w x13 studied the effect of pairs of modulators on the
accumulation of daunorubicin in a multidrug resistant
P388 cell line and showed how it was possible to
analyze interactions between reversers in terms of
cooperative, competitive and non-competitive mod-
els. We have applied their analysis at the level of the
ATPase activity of P-glycoprotein, and find that in
addition to these three categories of interaction, al-
losteric effects can also be demonstrated. In certain
cases, binding of one substrate is associated with a
marked increase in the Hill number that describes the
stimulation by a second substrate molecule. Thus,
effects beyond mere additivity have been demon-
strated and could be useful in developing modulator
strategies based on the combining of reversers of
P-glycoprotein.
2. Materials and methods
2.1. Tumor cells
The CHO cell line CR1R12 kindly made available
for us by Dr Alan E. Senior, University of Rochester
.Medical Center, New York, USA , was used. The
cells were maintained in a-MEM minimal essential
.medium containing 10% fetal calf serum and 5
mgrml colchicine.
2.2. Isolation of microsomal membranes
The cells were washed with Ringer’s medium
NaCl, 148.7 mM; K HPO , 2.55 mM; KH PO ,2 4 2 4
.0.45 mM; MgSO , 1.2 mM; pH 7.4 before being4
resuspended in 10 ml lysis buffer Hepes-Tris, 10
mM; EDTA, 5 mM; EGTA, 5 mM; dithiothreitol, 2
. mM; pH 7.4 containing protease inhibitors phenyl-
methylsulfonyl fluoride, 2 mM; aprotinin, 5 mgrml;
.pepstatin, 10 mgrml; leupeptin, 10 mgrml . This
and all subsequent steps were performed at 48C. Cells
were lysed by nitrogen cavitation Parr Instrument
.Co., Moline, IL, USA at 1200 psi for 20 min. Nuclei
were sedimented by centrifugation at 300=g for 10
min, and subsequently mitochondria were removed
by centrifugation at 4000=g for 10 min. In a third
 .and final centrifugation 45 000=g, 60 min the
microsomal fraction was sedimented. The pellet was
resuspended in lysis buffer and homogenized by aspi-
ration ten times through a 27 gauge syringe. Aliquots
 .of 150 ml containing 1–2 mg proteinrml were
frozen in N and stored at y808C until use.2l.
2.3. ATPase acti˝ity assay
The ATPase activity of P-glycoprotein was deter-
w xmined according to Borgnia et al. 14 , by quantitat-
ing the release of inorganic phosphate from ATP.
Each series of experiments was carried out in a
96-well microtiter plate, with reaction volumes of 50
mlrwell ATPase assay medium ATP, 3 mM; KCl,
50 mM; MgSO , 2.5 mM; dithiothreitol, 3 mM;4
Tris-HCl, 25 mM; EGTA, 0.5 mM; ouabain, 2 mM;
.azide, 3 mM; pH 7.0 . Incubation with the various
drugs was started by transferring the plate from ice to
378C for 30 min, and terminated by addition of 200
ml ice-cold stopping medium ammonium molybdate,
 .  .0.2% wrv ; sulfuric acid, 1.3% vrv ; SDS, 0.9%
 .  .wrv ; trichloroacetic acid, 2.3% wrv ; freshly pre-
 ..pared ascorbic acid, 1% wrv to each well. After
30 min incubation at room temperature, the released
phosphate was quantitated colorimetrically in a mi-
 .cro-plate reader Bio-Tek Instruments, VT USA at
620 nm. Samples incubated with 500 mM vanadate
were obtained in parallel and subtracted from the
measurements.
2.4. Chemicals
 .Verapamil D-verapamil was kindly provided by
 .Knoll AG Ludwigshafen, Germany . Cyclosporin A
was a kind gift from Sandoz now Novartis, Basel,
.Switzerland . All other chemicals were of analytical
grade, purchased either from Merck Darmstadt, Ger-
.  .many or from Sigma St. Louis, MO, USA .
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3. Results
Fig. 1A depicts the dependence of the ATPase
activity of P-glycoprotein on the concentration of
verapamil at four different concentrations of vana-
date. The same data transformed to the linear forms
of 1rV versus 1rS are shown as the inset. At all
concentrations of verapamil, increasing levels of
vanadate inhibited the ATPase. As is clear from the
inset, the K for verapamil’s effect in activating them
ATPase does not change with the vanadate concentra-
tion, showing that vanadate is a non-competitive
inhibitor of verapamil activation. In contrast, Fig. 1B
shows an analogous plot and replot for the pair
cyclosporin A and verapamil. Here, the Lineweaver-
Burke plot shows that cyclosporin acts as a competi-
tive inhibitor of verapamil-stimulated ATPase activ-
ity.
A different pattern of behavior is found for the pair
 .daunorubicin and verapamil Fig. 2A . Here, increas-
ing daunorubicin changes the nature of the depen-
dence of activity on verapamil concentration, in that
 .  .  .Fig. 1. Kinetics of inhibition of the verapamil-stimulated P-glycoprotein ATPase activity by A vanadate at 0 ‘ , 1 mM v , 5 mM
 .  .  .  .  .  .  .  .  .^ , and 10 mM ’ , and B cyclosporin A at 0 ‘ , 0.1 mM v , 0.5 mM ^ , and 1.0 mM ’ . The curves in A and B have
 .  . been fitted to the Michaelis-Menten equation: VsV q V yV Sr SqK . The insets are Lineweaver-Burk replots 1rV versus0 max 0 m
.  . I  . I1rS of the data. A Vanadate, non-competitive inhibition. K is obtained from V sV r 1q IrK , where V is the maximali max max i max
 .activity in the presence of the inhibitor, I. B Cyclosporin A, competitive inhibition. K is given by: 1rVs1rV qK rVi max m max
 . .1q IrK 1rS .i
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Fig. 2. Kinetics of inhibition of the verapamil-stimulated ATPase
 .  .  .activity of P-glycoprotein by A daunorubicin DNR at 0 ‘ , 1
 .  .  .  . mM v , 5 mM ^ , and 10 mM ’ , and B gramicidin S GR
.  .  .  .  .S at 0 ‘ , 0.1 mM v , 0.5 mM ^ , and 1.0 mM ’ . The
curves are obtained by curve-fitting to a modified form of the
 . n  n .Michaelis-Menten equation: V sV q V yV S r S q K ,0 max 0 i
which includes the Hill number, n, to be fitted. The listed K ,m
and Hill coefficients are obtained from the sigmoidal curve fits.
the Hill coefficient increases from ns1 to ns1.7
with daunorubicin. The Michaelis constant for vera-
pamil, however, remains unchanged as daunorubicin
increases. Thus, daunorubicin and verapamil interact
non-competitively, but binding of daunorubicin to
P-glycoprotein affects the kinetic interaction between
verapamil and P-glycoprotein. A very similar pattern
is observed for the pair gramicidin S and verapamil
 .Fig. 2B . Again, interaction between these two mod-
ulators is non-competitive, but the binding of grami-
cidin S affects the kinetics of interaction between
Fig. 3. Kinetics of inhibition of the verapamil-stimulated P-glyco-
 .  .  .protein ATPase activity by A vinblastine at 0 ‘ , 1 mM v ,
 .  .  .  .5 mM ^ , and 10 mM ’ , and B colchicine at 0 ‘ , 100
 .  .  .mM v , 500 mM ^ , and 1000 mM ’ . It has only been
 .possible to fit the curves without additional drug ‘ to the
Michaelis-Menten equation.
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verapamil and P-glycoprotein, the Hill number in-
creasing from 1 at zero gramicidin S to 1.8 at 1 mM.
The data depicted in Fig. 3 display a variation on
 .this pattern. Both for vinblastine Fig. 3A and for
 .colchicine Fig. 3B , at the highest concentrations of
these transport substrates verapamil apparently exerts
an inhibitory effect at low concentrations, while acti-
vation occurs at higher verapamil levels.
Finally, a quite different pattern is found when one
studies the interaction between two modulators, both
of which stimulate the ATPase activity. Fig. 4A
shows a plot similar to those of Figs. 1–3 but now
for the pair progesterone and verapamil. Here, a low
concentration of progesterone acts additively with
verapamil in stimulating the ATPase activity, but at
the highest progesterone level verapamil acts as an
inhibitor, even at the lowest verapamil concentration.
For clarity, in Fig. 4A only three concentrations of
progesterone are depicted, although intermediate con-
centrations in this range were studied; the ATPase
activity profiles changed continuously from stimula-
 .tory up to 6.3 mM progesterone to pure inhibitory
 .above 25 mM progesterone . From this same series
of experiments the data have also been plotted as
ATPase activity against progesterone concentration
 .Fig. 4B . With increasing verapamil, the apparent
affinity of P-glycoprotein for progesterone increases
in that stimulation occurs at lower concentrations of
progesterone. This is illustrated in the inset of Fig.
4B. Verapamil decreases the K of progesteronem
with a K of 0.61 mM. Thus, verapamil and proges-i
terone act cooperatively. Higher levels of proges-
terone and verapamil induce inhibition of the ATPase
activity.
Similar experiments have been performed with six
other transport substrates and modulators of the P-
 .glycoprotein ATPase data not shown . Those behav-
ing like daunorubicin and gramicidin S i.e. with a
Fig. 4. Kinetics of the combined effect of verapamil and proges-
 .terone on the P-glycoprotein ATPase. A The fractional ATPase
activity as a function of verapamil concentration at 0, 6.3 mM,
 .and 100 mM progesterone. B The ATPase activity as a function
 .  .of progesterone concentration at 0 ‘ , 0.4 mM v , 6.3 mM
 .  .  .^ , 50 mM ’ , and 100 mM \ verapamil. The inset shows
how the K of progesterone varies with the verapamil concentra-m
tion.
.profile similar to Fig. 2 were amiodarone, epiru-
bicin, and gramicidin D. Those behaving like proges-
 .terone Fig. 4 were amitriptyline, diltiazem, and
R-propranolol.
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4. Discussion
The interactions between verapamil and other
transport substrates and modulators of P-glycoprotein
are complex but can be classified into four major
categories. The first, and simplest, is represented by
the pair in Fig. 1A. Here, verapamil and vanadate
behave in a strictly non-competitive fashion, in that
the Michaelis constant, K , for verapamil’s stimula-m
tion of the ATPase does not change with the vanadate
concentration. This is consistent with the mode of
action of vanadate, interacting with the catalytic do-
w xmain of the P-glycoprotein ATPase 15 and not with
the substrate binding site. Vanadate is a known transi-
tion state analog in phosphoryl transfer reactions as it
easily forms a pentacovalent bipyramidal structure
similar to that of a phosphate ester during hydrolysis
w x16 . Thus, enzymes, such as the P-type ATPases
 q q 2q 2q .e.g. the Na rK -, Ca -, and Mg -ATPases ,
which employ a covalent phosphorylated intermedi-
ate, are most sensitive to vanadate inhibition with K i
w xvalues in the nanomolar concentration range 16,17 .
That the P-glycoprotein ATPase is inhibited by vana-
date could indicate, that a pentacoordinate phospho-
rus intermediate exists during the catalytic cycle, but
the relatively low sensitivity towards vanadate inhibi-
 .tion high K suggests that the reaction intermediatei
is not of the co˝alent phosphorylated type. This
notion is supported by our failure to identify a cova-
 .lent, phosphorylated intermediate data not shown ,
w xin agreement with previous such studies 18,19 .
The next-simplest category is represented by Fig.
1B, the pair verapamil and cyclosporin A. Here the
K of verapamil increases with the cyclosporin con-m
centration. Cyclosporin A behaves as a strict competi-
tive inhibitor with a K of 74"22 nM, comparablei
to that found for the inhibition of daunorubicin pump-
ing in Ehrlich ascites cells Litman et al., ATPase
activity of P-glycoprotein related to emergence of
drug resistance in Ehrlich ascites tumor cell lines,
.BBA, this issue and multidrug resistant P388 cells
w x w x13 and the values reported Rao et al. 20 and by
ourselves Litman et al., Structure-activity relation-
ships of P-glycoprotein interacting drugs: kinetic
characterization of their effects on ATPase activity,
.BBA, this issue for inhibition of P-glycoprotein
ATPase activity. These findings suggest that cy-
closporin A overlaps with verapamil on the same site
on P-glycoprotein, confirming the suggestion of
w xAyesh et al. 13 .
Category three is represented by Fig. 2A,B. Here,
increasing concentrations of daunorubicin or of gram-
icidin S induce a change in the shape of the dose-re-
sponse curves for verapamil-stimulated ATPase activ-
ity from simple Michaelis-Menten to sigmoidal kinet-
ics. The K for verapamil does not change withm
increasing daunorubicin or gramicidin S, so that their
interactions with verapamil are non-competitive. This
means that verapamil and daunorubicin or grami-
.cidin S are able to bind simultaneously to P-glyco-
protein, and at different sites which may interact
allosterically. The increase in the Hill coefficient
strongly suggests that the allosteric change has, most
interestingly, induced the phenomenon of cooperativ-
ity between pairs of verapamil molecules. The find-
ing with daunorubicin is in agreement with the work
w x w xof Pereira et al. 21 and Spoelstra et al. 22 , describ-
ing non-competitive interactions between verapamil
and the anthracyclines.
The next category, which is represented in Fig. 3,
displays a variation on the ATPase activity patterns
 .of Fig. 2. Here, both vinblastine Fig. 3A and
 .colchicine Fig. 3B , at high concentrations appar-
ently induce an inhibitory effect of verapamil at low
concentrations, while activation occurs at higher ver-
apamil levels. The complexity of the activation pro-
files in the presence of the higher concentrations of
vinblastine and colchicine has prevented us from
extracting K values for verapamil, so we can notm
establish quantitatively whether or not the interac-
tions here are competitive. Nevertheless, the fact that
the shapes of the verapamil activation profiles have
 .been changed by colchicine or by vinblastine
strongly suggests that the two drugs are being simul-
taneously bound to P-glycoprotein as Ayesh et al.
suggested in the case of vinblastine and verapamil
w x.13 . Interestingly, a marked effect of colchicine in
inhibiting the ATPase is seen at all levels of vera-
pamil, whereas colchicine on its own seldom displays
any inhibitory effect.
The final category is represented by progesterone
 .Fig. 4 , the affinity of which is increased rather than
reduced by the presence of verapamil. Such an in-
crease is the very opposite of competition and is,
rather, an example of cooperative behavior. From the
inset to Fig. 4B, showing the decrease in K form
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progesterone with increasing verapamil concentra-
tion, we derived the K value for verapamil which isi
similar to the K for ATPase activation by vera-m
pamil alone Litman et al., Structure-activity relation-
ships of P-glycoprotein interacting drugs: kinetic
characterization of their effects on ATPase activity,
.BBA, this issue . This suggests that the site at which
verapamil exerts its effect on the affinity of proges-
terone is the same site at which verapamil stimulates
the ATPase. As verapamil increases the affinity for
progesterone, the two modulators must be bound
simultaneously. Fig. 4A shows that at high levels of
progesterone verapamil acts as a very effective in-
hibitor of the ATPase activity. It would appear that
progesterone has increased the affinity of verapamil
for its inhibitory site on P-glycoprotein from 100 mM
Litman et al., Structure-activity relationships of P-
glycoprotein interacting drugs: kinetic characteriza-
tion of their effects on ATPase activity, BBA, this
.issue to 3.5 mM. Correspondingly, verapamil in-
creases the affinity of progesterone for its inhibitory
site. Such behavior might indicate that the inhibitory
effects found at high substrate concentrations arise
from specific interactions with P-glycoprotein, rather
than being merely nonspecific membrane perturba-
w xtions 23 .
It might be interesting to speculate that the posi-
tive, cooperative interactions between verapamil and
progesterone represent an aspect of the relation be-
tween affinity and surface area that we demonstrated
in Litman et al., Structure-activity relationships of
P-glycoprotein interacting drugs: kinetic characteriza-
tion of their effects on ATPase activity, BBA, this
issue. There, we showed that the affinity of a trans-
port substrate or modulator for P-glycoprotein was
proportional to the Van der Waals surface area of the
drug. It is possible that when two different drugs are
present, each binding to the large interacting surface
of P-glycoprotein, each can contribute to the overall
interaction with P-glycoprotein leading to a combined
effect which is greater than that given by either drug
alone.
Most of the transport substrates and modulators
that we have studied daunorubicin, epirubicin, vin-
blastine, the gramicidins, colchicine, and proges-
.terone seem to bind to P-glycoprotein at a different
site or sites from that to which verapamil binds. In
contrast, cyclosporin A and verapamil at least share
overlapping sites on P-glycoprotein. Our study has
underscored the complexity of the substrate binding
sites on P-glycoprotein, information which can form
the basis for the development of improved modula-
tors for this clinically important protein.
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